Here, in order to accelerate the clinical implementation of transcriptional inhibitors in NB, we investigate the ability of CYC065 (fadraciclib), a selective inhibitor of CDK9 and CDK2 that has reached clinical early phase trials, to selectively target MYCN-amplified tumors via multiple mechanisms. The gene discussed is MYCN; the disease is neuroblastoma.